Diabetic Nephropathy Clinical Trial
Official title:
A Clinical Study on the Application of Enhanced Recovery After Surgery for Simultaneous Pancreas-kidney Transplantation
NCT number | NCT06095544 |
Other study ID # | 2020-hs-67 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2021 |
Est. completion date | June 1, 2023 |
Verified date | October 2023 |
Source | Second Affiliated Hospital of Guangzhou Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
108 patients underwent elective SPK surgery were randomly divided into ERAS group (E) and routine care group (T). The ERAS group was consisted of evidenced-based systematic optimization approaches, while the control group received routine care.
Status | Completed |
Enrollment | 90 |
Est. completion date | June 1, 2023 |
Est. primary completion date | December 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 62 Years |
Eligibility | Inclusion Criteria: 1. Patients were aged 20-62 years 2. Body mass index (BMI) of 18.5-32.9 kg/m2 3. Voluntary participation for elective SPK surgery 4. ERSD and DN patients waiting for SPK transplantation surgery. Exclusion Criteria: 1. History of allergy to narcotic drugs 2. cardiopulmonary insufficiency 3. congestive heart failure 4. myasthenia gravis 5. neurological disease 6. mental illness 7. severe liver dysfunction 8. hyperkalaemia 9. malignant hyperthermia 10. unwilling to participate in the study for any reason, or had participated in another study within the 3 months |
Country | Name | City | State |
---|---|---|---|
China | Second affiliated hospital of Guangzhou Medical University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital of Guangzhou Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Length of hospital stay (LoS) | Record the time for SPK recipients of LoS (days) | Record all the period time from the day of admiting to hospital to the day of discharge from hospital(days). | |
Primary | Hospital costs (US dollar) | The total cost of treatment for the patients. | Total costs(dollar) of the patients spended from the day of admiting to hospital to the day of discharge from hospital(days). | |
Secondary | Perioperative complications | 48 hours post-operative analgesia score (NRS), the incidence of post-operative nausea and vomiting (PONV) , urinary catheter removal time by 7 days , post-operative gastric tube indwelling time, the incidence of ambulation within 6 days | After the surgery acomplishment(see detail above):record the NRS within 40hours after the surgery, occurrence rate of the PPCs within 2 weeks after the surgery, ocurrence rate of the ambulation within 6 days after the surgery, etc. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04562025 -
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
|
N/A | |
Not yet recruiting |
NCT03658317 -
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
|
N/A | |
Recruiting |
NCT02501772 -
The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy
|
N/A | |
Completed |
NCT02829177 -
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT02251067 -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
|
Phase 2 | |
Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
Completed |
NCT01440257 -
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT01273675 -
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00317954 -
Spironolactone in Diabetic Nephropathy
|
Phase 4 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Not yet recruiting |
NCT05061459 -
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
|
||
Completed |
NCT01935167 -
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01673204 -
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|
Phase 4 | |
Completed |
NCT01726816 -
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01458158 -
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
|
N/A | |
Completed |
NCT01447147 -
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01476501 -
Vitamin D Supplementation in Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01003236 -
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT00535925 -
Nephropathy In Type 2 Diabetes and Cardio-renal Events
|
Phase 4 |